[Low-dose gemcitabine concurrent with radiation therapy for locally advanced pancreatic carcinoma].
We evaluated the efficacy and feasibility of low-dose gemcitabine concurrent with radiation as adjuvant therapy. Nine cases of locally far advanced unresectable pancreatic cancer were enrolled in this study. Intraoperative radiation was carried out in every case using eight or ten centimeter cones with a radiation dose of twenty to twenty five Gy. Postoperative radiation was two Gy per day on weekdays for five weeks. Low-dose gemcitabine (40 mg/m2) once a week was administered prior to radiation. A grade 3 adverse event occurred in three cases. CA19-9 decreased 60.1% and DUPAN-2, 52.6%. CT scan confirmed a necrotic change and a decrease of the tumor size. Average survival time was ten months. Peritoneal dissemination was the recurrence pattern. In conclusion, low-dose gemcitabine concurrent with radiation therapy may contribute to local control of the disease. However, peritoneal dissemination must be overcome to prolong survival.
Baba
Hiroyuki
H
Dept. of Surgery, Tokyo Metropolitan Komagome Hospital.
Kurata
Masano
M
Tsuruta
Koji
K
Okamoto
Atsutake
A
Karasawa
Katsuyuki
K
D000951:Antigens, Neoplasm / Q000097:blood; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D018395:CA-19-9 Antigen / Q000097:blood; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000628:therapy*; D011879:Radiotherapy Dosage; D000093542:Gemcitabine
D000951:Antigens, Neoplasm; D000964:Antimetabolites, Antineoplastic; D018395:CA-19-9 Antigen; C042317:DU-PAN-2 antigen, human; D003841:Deoxycytidine; D000093542:Gemcitabine